// App-Quantinova.ai

BSH2020‐PO‐102 : An immunocompetent, spontaneous mouse model of DLBCL for studying the response to R‐CHOP and identifying new treatment targets

Researchers

Presenter

  • B. Maybury

Principal Investigators

  • J. Fitzgibbon

  • D. Calado

Medical Centers

  • Francis Crick Institute

  • Barts Cancer Institute, QMUL, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • Interferon regulatory factor 4

  • B-cell lymphoma 6

  • Nuclear factor kappa-light-chain-enhancer of activated B cells

  • B-lymphocyte antigen CD20

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2

  • Proliferation marker protein Ki-67

  • cMYC

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Prednisolone

  • Vincristine

  • Doxorubicin

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved